The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
about
T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expressionLow-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilizationNeuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury.Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome?C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferationRecent advances in the understanding of mastocytosis: the role of KIT mutations.Clonality and molecular pathogenesis of mastocytosis.Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.KIT and mastocytosis.Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives.Glycosaminoglycan silencing by engineered CXCL12 variants.Combination therapy for KIT-mutant mast cells: targeting constitutive NFAT and KIT activity.The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene.Mast cell chemotaxis - chemoattractants and signaling pathways.Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K).Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum.Impaired neutrophil chemotaxis in chronic obstructive pulmonary disease.
P2860
Q21146439-D549A5A7-1C0C-45ED-A567-E88D321BD37CQ24646424-E6B4DAF4-713D-4B48-B5FE-972E86279172Q33202586-279B763F-F546-434A-B153-89A845574B18Q33208353-CBB9FED5-1C7E-4E2D-9D50-43E2626F41F0Q33658543-D938548E-0236-4678-A25F-D546A5804B20Q34009824-279AC9EC-7067-47CB-8517-2C10FE9FF23EQ34635424-82C7EB38-D1F9-47EC-A3A5-B2C4755468D5Q36182758-306FA2ED-CE84-4C98-B396-CA650037C38BQ36842503-3C9B9C5F-D578-4E6D-A4FB-1B33BA6FA8C0Q37195681-8FBB4E20-F447-4567-82A5-BA0A109268B6Q37262426-E48F88CF-F29C-4B33-BB47-F57CAC194CDEQ37379320-CF0F0EA0-B6BE-4635-9AD1-AAB74F129E5BQ37810130-C0F804D9-19D5-479B-A8B6-EFC6E0BF3B99Q38841772-6E170E2C-8BCE-4320-8148-6A3A367646D6Q38953475-BBBE0A81-7F5C-4E91-A1E5-9F7064B4C87FQ39876378-22264521-55D5-4A94-9140-A9D6EE0D4DE2Q40678754-67FE33CA-FB09-422C-A192-E40FE07A0C4EQ42177446-ABA4EECD-D4A2-49BE-8CD6-08882175DE8CQ46631742-4CB92F4A-51E2-443D-BC18-17E28FF096E5Q47999363-911E9C97-6897-4886-89F9-649EA1C069E8Q53587875-8E4E88A3-38D8-438F-97BA-2D385DCDF212
P2860
The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
@en
The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
@nl
type
label
The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
@en
The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
@nl
prefLabel
The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
@en
The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
@nl
P2093
P50
P356
P1433
P1476
The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.
@en
P2093
P304
P356
10.1182/BLOOD.V98.4.1195
P407
P577
2001-08-01T00:00:00Z